Literature DB >> 12356036

Adjuncts to opioid therapy.

Frederick J Goldstein1.   

Abstract

Administration of opioids to alleviate moderate to severe acute pain and chronic cancer pain is an established management process. However, advancements in clinical pharmacologic research have shown that opioids are also effective in chronic noncancerous pain. Many patients properly treated for prolonged periods with opioids develop tolerance and subsequently, physical dependence. This process is not necessarily harmful to the patient and will not cause the patient to develop an addiction (properly defined as psychologic dependence). For many patients who have been on opioid therapy for months or years, analgesic effectiveness tragically becomes less. In addition, opioid-induced constipation can be severe and cause pain; patients do not develop tolerance to this adverse reaction. Therefore, such issues become a management problem and require additional intervention. Currently, many different classes of drugs can serve as effective adjuncts to opioids for treatment of pain. Adding adjunctive medication to opioid therapy improves pain management primarily by nonopioid mechanisms of action. Clinical outcomes of such combinations include greater analgesia and attenuation of opioid-induced adverse reactions such as nausea and vomiting, constipation, sedation, and respiratory depression. Adjuncts include acetaminophen, antiarrhythmics, anticonvulsants, antidepressants, antipsychotics, baclofen, benzodiazepines, capsaicin, calcium channel blockers, clonidine hydrochloride, central nervous system stimulants, corticosteroids, local anesthetics, N-methyl-D-aspartate receptor antagonists, nonsteroidal antiinflammatory drugs, pentoxifylline, and scopolamine. Some adjuncts (eg, acetaminophen) are routinely used today, whereas others (eg, nifedipine [calcium channel blocker]) are used on a limited basis but have great potential for more widespread application. All professionals (eg, nurses, pharmacists, physicians, physicians' assistants, social workers, members of the clergy) involved in treating patients with unresolved pain recognize this to be an extraordinary and delicate time. It is when patients are likely to request physicians to provide some method to accelerate their death. Thus, inadequate analgesia can become a suicidogen, ie, any factor that causes a patient to want to commit suicide. Incorporation of adjuncts to opioid therapy can serve to lessen pain and improve quality of life for a suffering patient.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356036

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  15 in total

1.  Elucidation of mu-Opioid Gene Structure: How Genetics Can Help Predict Responses to Opioids.

Authors:  Luda Diatchenko; J Elliott Robinson; William Maixner
Journal:  Eur J Pain Suppl       Date:  2011-11-11

2.  Changes in medical and nursing care after admission to palliative care units: a potential method for improving regional palliative care.

Authors:  Ayumi Igarashi; Tatsuya Morita; Mitsunori Miyashita; Emi Kiyohara; Satoshi Inoue
Journal:  Support Care Cancer       Date:  2010-06-16       Impact factor: 3.603

Review 3.  Efficacy and Safety Considerations With Second-Generation Antipsychotics as Adjunctive Analgesics: A Review of Literature.

Authors:  Belinda Coronado; Jacob Dunn; Michael A Veronin; Justin P Reinert
Journal:  J Pharm Technol       Date:  2021-04-19

4.  Sex-specific role for serotonin 5-HT2A receptor in modulation of opioid-induced antinociception and reward in mice.

Authors:  Salvador Sierra; Karan H Muchhala; Donald K Jessup; Katherine M Contreras; Urjita H Shah; David L Stevens; Jennifer Jimenez; Xiomara K Cuno Lavilla; Mario de la Fuente Revenga; Kumiko M Lippold; Shanwei Shen; Justin L Poklis; Liya Y Qiao; William L Dewey; Hamid I Akbarali; M Imad Damaj; Javier González-Maeso
Journal:  Neuropharmacology       Date:  2022-02-17       Impact factor: 5.273

5.  Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain.

Authors:  Antonio Ortega-Alvaro; Ignacio Acebes; Gonzalo Saracíbar; Enrique Echevarría; Luis Casis; Juan Antonio Micó
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

6.  Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses.

Authors:  Kaori Yoshida; Daisuke Nishizawa; Takashi Ichinomiya; Tatsuya Ichinohe; Masakazu Hayashida; Ken-ichi Fukuda; Kazutaka Ikeda
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

7.  Antinociceptive interaction of (±)-CPP and propentofylline in monoarthritic rats.

Authors:  Francisco Morales; Luis Constandil; Teresa Pelissier; Alejandro Hernández; Claudio Laurido
Journal:  Arthritis Res Ther       Date:  2012-08-24       Impact factor: 5.156

Review 8.  Is there genetic polymorphism evidence for individual human sensitivity to opiates?

Authors:  Makoto Nagashima; Ryoji Katoh; Yasuo Sato; Megumi Tagami; Shinya Kasai; Kazutaka Ikeda
Journal:  Curr Pain Headache Rep       Date:  2007-04

9.  Expansion of the human mu-opioid receptor gene architecture: novel functional variants.

Authors:  Svetlana A Shabalina; Dmitri V Zaykin; Pavel Gris; Aleksey Y Ogurtsov; Josee Gauthier; Kyoko Shibata; Inna E Tchivileva; Inna Belfer; Bikashkumar Mishra; Carly Kiselycznyk; Margaret R Wallace; Roland Staud; Nikolay A Spiridonov; Mitchell B Max; David Goldman; Roger B Fillingim; William Maixner; Luda Diatchenko
Journal:  Hum Mol Genet       Date:  2008-12-22       Impact factor: 6.150

10.  Motor Cortex Stimulation for Pain Relief: Do Corollary Discharges Play a Role?

Authors:  Joaquim P Brasil-Neto
Journal:  Front Hum Neurosci       Date:  2016-06-28       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.